American Heart Journal
Volume 156, Issue 6 , Pages 1196-1200 , December 2008

Ejection fraction assessment and survival: An analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  • Lorne J. Gula, MD, MS

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationReprint requests: Lorne J. Gula, MD, London Health Sciences Centre, Arrhythmia Service, 339 Windermere Road, London, Ontario, Canada N6A 5A5.
    • ,
  • George J. Klein, MD

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Anne S. Hellkamp, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • David Massel, MD

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Andrew D. Krahn, MD

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Allan C. Skanes, MD

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Raymond Yee, MD, FRCPC

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Jill Anderson, RN

      Affiliations

    • Seattle Institute for Cardiac Research, Seattle, WA
    • ,
  • George W. Johnson, BSEE

      Affiliations

    • Seattle Institute for Cardiac Research, Seattle, WA
    • ,
  • Jeanne E. Poole, MD

      Affiliations

    • University of Washington Medical Center, Seattle, WA
    • ,
  • Daniel B. Mark, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Kerry L. Lee, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Gust H. Bardy, MD

      Affiliations

    • Seattle Institute for Cardiac Research, Seattle, WA
    • ,
  • for the SCD-HeFT Investigators

Received 29 May 2008 ,Accepted 5 August 2008.

References 

  1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–1940
  4. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–1890
  5. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  6. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738–3744
  7. Tang AS, Ross H, Simpson CS, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol. 2005;21(Suppl A):11–18
  8. Armstrong PW, Bogaty P, Buller CE, et al. The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. Can J Cardiol. 2004;20:1075–1079
  9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1–E211
  10. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006;27:2099–2140
  11. Centers for Medicare & Medicaid Services . Pub 100-03 Medicare National Coverage Determinations. Centers for Medicare & Medicaid Services. Available at http://www.cms.hhs.gov/transmittals/downloads/R29NCD.pdf.Last accessed August 4, 2008
  12. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J. 2000;21:1387–1396
  13. Naik MM, Diamond GA, Pai T, et al. Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol. 1995;25:937–942
  14. Bernard Y, Meneveau N, Boucher S, et al. Lack of agreement between left ventricular volumes and ejection fraction determined by two-dimensional echocardiography and contrast cineangiography in postinfarction patients. Echocardiography. 2001;18:113–122
  15. Bardy GH. In: The Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT), arrhythmia treatment and therapy: evaluation of clinical trial evidence. New York: Marcel Dekker; 2000;p. 323–342
  16. Rashid H, Exner DV, Mirsky I, et al. Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction). Am J Cardiol. 1999;84:299–303

 SCD-HeFT was supported by grants (UO1 HL55766, UO1 HL55297, and UO1 HL55496) from the National Heart, Lung, and Blood Institute, National Institutes of Health (both in Bethesda, MD), and by Medtronic (Minneapolis, MN), Wyeth-Ayerst Laboratories (Madison, NJ). This substudy was supported by a grant from Medtronic of Canada (Mississauga, Ontario, Canada).

 Author Disclosures: Dr Bardy: Research funding from Medtronic and Wyeth-Ayerst Pharmaceuticals; founder of, board member of, consultant to, and equity holder in Cameron Health (San Clemente, CA). Dr Gula: grant support from Medtronic of Canada. Dr Klein: consultant fees from Medtronic. Dr Krahn: consultant fees from Boston Scientific and Transoma. Dr Lee: research funding from Medtronic and Wyeth-Ayerst Pharmaceuticals. Dr Mark: grant support and speaking fees from Medtronic. Dr Poole: speaking fees from Boston Scientific (Natick, MA), Medtronic, and Biotronic (Ann Arbor, MI). Dr Yee: Consultant fees from Medtronic.

 Guest editor: Gary S. Francis, MD.

PII: S0002-8703(08)00668-6

doi: 10.1016/j.ahj.2008.08.007

American Heart Journal
Volume 156, Issue 6 , Pages 1196-1200 , December 2008

Article Tools

* Image Usage & Resolution